^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A clinical trial of fecal bacteria transplantation combined with pembrolizumab, pemetrexed and carboplatin as a first-line treatment of EGFR and ALK wild-type metastatic non-squamous, non-small cell lung cancer
Excerpt:
...For non squamous NSCLC patients not confirmed as wild-type EGFR and wild-type ALK, tumor samples (archived or fresh, primary or metastatic) need to be collected for evaluation of EGFR and ALK examination (in local laboratory or central laboratory) before enrollment. ...
Trial ID:
Source:
Title:
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
Excerpt:
...EGFR and ALK wild type...
Trial ID:
More C2 evidence
Source:
Title:
89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer
Excerpt:
...Have a histologically or cytologically confirmed diagnosis of stage IV, EGFR wt and EML4/ALK fusion negative NCSLC and have received at least one line of platinum based doublet chemotherapy and disease progression by RECIST 1.1 on the last systemic treatment....
Trial ID:
Source:
Title:
89Zirconium-labeled pembrolizumab in pembrolizumab treated patients with non-small-cell lung cancer – a feasibility study 89Zirconium gelabeled Pembrolizumab in patiënten met niet-kleincellig longkanker die worden behandeld met Pembrolizumab – een haalbaarheidsstudie.
Excerpt:
...Have a histologically or cytologically confirmed diagnosis of stage IV, EGFR wt and EML4/ALK fusion negative NCSLC and have received at least one line of platinum based doublet chemotherapy and disease progression by RECIST 1.1 on the last systemic treatment.Be willing and able to provide written informed consent/assent for the trial.Be 18 years of age or older on day of signing informed consent.Have measurable disease based on RECIST 1.1. ...
Trial ID:
Source:
Title:
Genetic Predictors of Benefit to Pembrolizumab
Excerpt:
...- Chemotherapy naïve NSCLC patients.For NSCLC patients with lung adenocarcinoma, tumors must be Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) wild-type; if a Kirsten Ras (KRAS) mutation is detected, EGFR and ALK testing is...
Trial ID:
Source:
Title:
Pembrolizumab in Elderly Patients With Advanced Lung Cancer
Excerpt:
...Epidermal Growth Factor receptor (EGFR) and Anaplastic lymphoma kinase (ALK) have to be wild-type....
Trial ID:
Less C2 evidence
Source:
Title:
WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Published date:
07/12/2022
Excerpt:
Until Dec. 31st 2021, the median follow-up was 5.6 months. ORR was 57.6% in sintilimab arms vs. 42.9% in pembrolizumab arms, and the confirmed ORR was 45.5% (15/33) vs. 28.6% (10/35), separately. (Figure 1). The disease control rate was 87.9% vs. 91.4% in sintilimab and pembrolizumab arms, respectively. The primary endpoint was reached, with 15 confirmed PRs achieved in sintilimab arms. Survival data was still immature....This head-to-head study of PD-1 inhibitors suggested comparable tumor response and similar safety profile between sintilimab and pembrolizumab.
Source:
Title:
Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis
Published date:
10/30/2017
Excerpt:
Our objective was to assess the comparative effectiveness and tolerability of all second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR by a systematic review and network meta-analysis....For OS, nivolumab was more effective than docetaxel (hazard ratio (HR) 0.69, 95% credible interval (CrI) 0.56–0.83), pemetrexed (0.67, 0.52–0.83), erlotinib (0.68, 0.53–0.86), and gefitinib (0.66, 0.53–0.83). Pembrolizumab, atezolizumab, and pemetrexed plus erlotinib were also significantly more effective than docetaxel, pemetrexed, erlotinib, and gefitinib.
DOI:
10.1186/s12916-017-0954-x
